PLUS1
6.26
0.22 (3.64%)
0.22 (3.64%)
Upgrade to Real-Time
Regular Market
Best deals to access real time data! |
|
Big Cap Pro
Monthly Subscription
for only
|
|
Small Cap Basic
Monthly Subscription
for only
|
|
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
|
|
VAT not included
|
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Ardelyx Inc | ARDX | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded  |
|
|---|---|---|---|---|
| 0.22 | 3.64% | 6.26 | 13:16:08 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 6.20 | 6.15 | 6.41 | 6.04 |
| Bid Price | Ask Price | Spread | News | |
|---|---|---|---|---|
| 6.24 | 6.26 | 0.02 | - | - |
| Stock Trades | Traded Volume | VWAP | Dollar Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 3,181 | 688,616 | $ 6.30 | $ 4,339,094 | 412,603 | 4.22 - 8.815 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 13:16:04 | 100 | $ 6.26 | USD |
Ardelyx Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 564.96M | 90.25M | 73.55M | $ 5.28M | $ - | -1.47 | -6.10 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | 0.00% | -270.61k | 2.60% |
Ardelyx News
| Date | Time | Source | News Article |
|---|---|---|---|
| 11/23/2020 | 08:00 | PR Newswire (US) | Ardelyx to Present at the Piper Sandler 32nd Annual Virtual.. |
| 11/10/2020 | 08:00 | PR Newswire (US) | Ardelyx to Present at the Jefferies Virtual London.. |
| 11/06/2020 | 08:00 | PR Newswire (US) | Ardelyx to Webcast Virtual Analyst Day |
| 11/05/2020 | 08:08 | Edgar (US Regulatory) | Quarterly Report (10-q) |
| 11/05/2020 | 08:03 | Edgar (US Regulatory) | Current Report Filing (8-k) |
| 11/05/2020 | 08:00 | PR Newswire (US) | Ardelyx Reports Third Quarter 2020 Financial Results and.. |
| 10/22/2020 | 10:00 | PR Newswire (US) | Ardelyx and Kyowa Kirin Highlight New Data Supporting the.. |
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ARDX Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 6.00 | 6.41 | 5.9893 | 6.18 | 373,095 | 0.26 | 4.33% |
| 1 Month | 5.74 | 6.41 | 5.33 | 5.89 | 406,459 | 0.52 | 9.06% |
| 3 Months | 5.91 | 6.97 | 4.81 | 5.73 | 488,837 | 0.35 | 5.92% |
| 6 Months | 7.05 | 7.57 | 4.81 | 6.12 | 541,002 | -0.79 | -11.21% |
| 1 Year | 8.05 | 8.815 | 4.22 | 6.65 | 692,470 | -1.79 | -22.24% |
| 3 Years | 6.65 | 10.4343 | 1.60 | 5.54 | 533,171 | -0.39 | -5.86% |
| 5 Years | 19.25 | 20.73 | 1.60 | 6.32 | 444,409 | -12.99 | -67.48% |
Ardelyx Description
| Ardelyx Inc is a biotechnology company focused on the discovery, development, and commercialization of molecule and polymeric therapeutics to treat the gastrointestinal tract and cardiorenal diseases. The company has a proprietary drug discovery and design platform. Its lead product candidate is tenapanor, which aims to reduce the absorption of dietary sodium and phosphorus for the treatment of kidney disease, irritable bowel syndrome with constipation, and hyperphosphatemia in patients with dialysis. |
